دورية أكاديمية
أعرض في EDS

Phylogenetic and full-length genome mutation analysis of SARS-CoV-2 in Indonesia prior to COVID-19 vaccination program in 2021.

التفاصيل البيبلوغرافية
العنوان: Phylogenetic and full-length genome mutation analysis of SARS-CoV-2 in Indonesia prior to COVID-19 vaccination program in 2021.
المؤلفون: Nidom RV; Coronavirus and Vaccine Formulation Research Group, Professor Nidom Foundation, Surabaya, Indonesia.; Riset AIRC Indonesia, Surabaya, Indonesia., Indrasari S; Coronavirus and Vaccine Formulation Research Group, Professor Nidom Foundation, Surabaya, Indonesia.; Riset AIRC Indonesia, Surabaya, Indonesia., Normalina I; Coronavirus and Vaccine Formulation Research Group, Professor Nidom Foundation, Surabaya, Indonesia.; Riset AIRC Indonesia, Surabaya, Indonesia., Nidom AN; Coronavirus and Vaccine Formulation Research Group, Professor Nidom Foundation, Surabaya, Indonesia., Afifah B; Coronavirus and Vaccine Formulation Research Group, Professor Nidom Foundation, Surabaya, Indonesia., Dewi L; Faculty of Medicine, Universitas Hang Tuah, Surabaya, Indonesia., Putra AK; Dr. Ramelan Naval Hospital, Surabaya, Indonesia., Ansori ANM; Coronavirus and Vaccine Formulation Research Group, Professor Nidom Foundation, Surabaya, Indonesia.; Program Pendidikan Magister Menuju Doktor Untuk Sarjana Unggul (PMDSU) Program - Batch III, Ministry of Education, Culture, Research, and Technology, Jakarta, Indonesia., Kusala MKJ; Coronavirus and Vaccine Formulation Research Group, Professor Nidom Foundation, Surabaya, Indonesia.; Program Pendidikan Magister Menuju Doktor Untuk Sarjana Unggul (PMDSU) Program - Batch III, Ministry of Education, Culture, Research, and Technology, Jakarta, Indonesia., Alamudi MY; Coronavirus and Vaccine Formulation Research Group, Professor Nidom Foundation, Surabaya, Indonesia., Nidom CA; Coronavirus and Vaccine Formulation Research Group, Professor Nidom Foundation, Surabaya, Indonesia.; Riset AIRC Indonesia, Surabaya, Indonesia.; Faculty of Veterinary Medicine, Universitas Airlangga, Surabaya, Indonesia.
المصدر: Bulletin of the National Research Centre [Bull Natl Res Cent] 2021; Vol. 45 (1), pp. 200. Date of Electronic Publication: 2021 Nov 21.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Berlin Heidelberg Country of Publication: Germany NLM ID: 101755158 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2522-8307 (Electronic) Linking ISSN: 11100591 NLM ISO Abbreviation: Bull Natl Res Cent Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: Berlin : Springer Berlin Heidelberg
Original Publication: Dokki, Cairo : National Research Centre
مستخلص: Background: Indonesia has started the big project of COVID-19 vaccination program since 13 January 2021 by employing the first shot of vaccine to the President of Indonesia as the outbreak and rapid transmission of COVID-19 have endangered not only Indonesian but the global health and economy. This study aimed to investigate the full-length genome mutation analysis of 166 Indonesian SARS-CoV-2 isolates as of 12 January 2021.
Results: All data of the isolates were extracted from the Global Initiative on Sharing All Influenza Data (GISAID) EpiCoV database. CoVsurver platform was employed to investigate the full-length genome mutation analysis of all isolates. This study also focused on the phylogeny analysis in unlocking the mutation of S protein in Indonesian SARS-CoV-2 isolates. WIV04 isolate that was originated from Wuhan, China was used as the virus reference according to the CoVsurver default. The result showed that a full-length genome mutation analysis of 166 Indonesian SARS-CoV-2 isolates was successfully generated. Every single mutation in S protein was described and then visualized by utilizing BioRender platform. Furthermore, it also found that D614G mutation appeared in 103 Indonesian SARS-CoV-2 isolates.
Conclusions: To sum up, this study helped to observe the spread of COVID-19 transmission. However, it also proposed that the epidemiological surveillance and genomics studies might be improved on COVID-19 pandemic in Indonesia.
Supplementary Information: The online version contains supplementary material available at 10.1186/s42269-021-00657-0.
Competing Interests: Competing interestsThe authors declare that they have no competing interests.
(© The Author(s) 2021.)
References: J Med Virol. 2020 Sep;92(9):1469-1474. (PMID: 32320059)
Vacunas. 2020 Jul-Dec;21(2):121-128. (PMID: 32837460)
Cell. 2020 Aug 20;182(4):812-827.e19. (PMID: 32697968)
Gene Rep. 2020 Dec;21:100860. (PMID: 32875166)
PLoS One. 2020 Sep 3;15(9):e0238344. (PMID: 32881907)
Infect Genet Evol. 2021 Apr;89:104724. (PMID: 33476804)
Nature. 2020 Apr;580(7805):576-577. (PMID: 32346146)
Rev Clin Esp (Barc). 2021 Jan;221(1):55-61. (PMID: 33998479)
Heliyon. 2020 Aug;6(8):e04743. (PMID: 32835122)
Lancet Infect Dis. 2020 Jun;20(6):631-633. (PMID: 32213329)
Cytometry A. 2020 Jul;97(7):662-667. (PMID: 32506725)
Am J Trop Med Hyg. 2020 Dec;103(6):2339-2342. (PMID: 33069265)
Indian J Med Res. 2020 Feb & Mar;151(2 & 3):200-209. (PMID: 32242873)
Osong Public Health Res Perspect. 2020 Jun;11(3):101-111. (PMID: 32528815)
BMJ. 2021 Jul 16;374:n1815. (PMID: 34272255)
Elife. 2020 Oct 28;9:. (PMID: 33112236)
Turk J Med Sci. 2020 Apr 15;50(SI-1):571-577. (PMID: 32293835)
Infect Genet Evol. 2020 Jul;81:104260. (PMID: 32092483)
Nat Commun. 2020 Nov 26;11(1):6013. (PMID: 33243994)
Infect Genet Evol. 2020 Oct;84:104390. (PMID: 32505692)
Med Drug Discov. 2021 Jun;10:100086. (PMID: 33681755)
Gene Rep. 2020 Jun;19:100682. (PMID: 32300673)
New Sci. 2021 Jan 9;249(3316):8-9. (PMID: 33518995)
Nat Med. 2020 Apr;26(4):450-452. (PMID: 32284615)
J Adv Res. 2020 Mar 16;24:91-98. (PMID: 32257431)
Pak J Med Sci. 2020 May;36(COVID19-S4):S73-S78. (PMID: 32582318)
Genomics Inform. 2020 Sep;18(3):e30. (PMID: 33017874)
Lancet. 2020 Mar 28;395(10229):1015-1018. (PMID: 32197103)
BMC Infect Dis. 2019 Jan 31;19(1):101. (PMID: 30704406)
Cell Host Microbe. 2021 Mar 10;29(3):463-476.e6. (PMID: 33592168)
J Med Virol. 2020 Jun;92(6):667-674. (PMID: 32167180)
Nat Med. 2021 Apr;27(4):620-621. (PMID: 33558724)
Sci Adv. 2020 Jul 1;6(27):. (PMID: 32937441)
J Infect. 2020 Jul;81(1):e24-e27. (PMID: 32283146)
Clin Infect Dis. 2021 Dec 16;73(12):2314-2317. (PMID: 33772259)
Lancet. 2020 Feb 29;395(10225):689-697. (PMID: 32014114)
CMAJ. 2021 Jul 12;193(27):E1059-E1060. (PMID: 34253551)
Arch Virol. 2020 Sep;165(9):2095-2098. (PMID: 32556599)
Nat Mater. 2020 Aug;19(8):810-812. (PMID: 32704139)
Biochem Biophys Rep. 2020 Dec 11;25:100847. (PMID: 33364445)
Lancet Infect Dis. 2020 May;20(5):533-534. (PMID: 32087114)
Cytokine Growth Factor Rev. 2020 Jun;53:1-9. (PMID: 32487439)
J Microbiol Immunol Infect. 2020 Jun;53(3):436-443. (PMID: 32307245)
Molecules. 2020 Dec 23;26(1):. (PMID: 33374759)
Emerg Infect Dis. 2021 May;27(5):1522-1524. (PMID: 33605869)
Euro Surveill. 2020 Apr;25(13):. (PMID: 32265007)
Lancet. 2020 Feb 15;395(10223):497-506. (PMID: 31986264)
Nat Med. 2021 Apr;27(4):717-726. (PMID: 33664494)
PeerJ. 2020 Dec 21;8:e10575. (PMID: 33391880)
Nat Med. 2021 Mar;27(3):440-446. (PMID: 33531709)
Nat Commun. 2020 Mar 27;11(1):1620. (PMID: 32221306)
Science. 2020 Jul 17;369(6501):330-333. (PMID: 32366695)
Nature. 2021 May;593(7858):266-269. (PMID: 33767447)
Int J Mol Sci. 2020 Apr 10;21(7):. (PMID: 32290293)
Z Gesundh Wiss. 2022;30(1):259-261. (PMID: 32837835)
BMC Med Genomics. 2021 Jun 1;14(1):144. (PMID: 34074255)
Cytokine. 2020 Dec;136:155256. (PMID: 32866898)
Genomics. 2020 Sep;112(5):3588-3596. (PMID: 32353474)
فهرسة مساهمة: Keywords: COVID-19; Genome analysis; Indonesia; SARS-CoV-2; Spike protein
تواريخ الأحداث: Date Created: 20211129 Latest Revision: 20221101
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC8606223
DOI: 10.1186/s42269-021-00657-0
PMID: 34840498
قاعدة البيانات: MEDLINE
الوصف
تدمد:2522-8307
DOI:10.1186/s42269-021-00657-0